WED-215 HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning
Giulia Angelini(Università Cattolica del Sacro Cuore), Geltrude Mingrone(University of the Sacred Heart), Aldo Trylesinski(Novartis (Switzerland)), Caterina Guidone(Agostino Gemelli University Polyclinic), Luca Miele(Agostino Gemelli University Polyclinic), Stephen A. Harrison(Pinnacle Clinical Research), Sara Russo(Università Cattolica del Sacro Cuore), Erminia Lembo(Università Cattolica del Sacro Cuore), Antonio Liguori, Ornella Verrastro(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k